Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.
New York City aims to expand PrEP and PEP access by educating more clinicians that serve women.
April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.
Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.
The global increase in sexually transmitted infections was a major focus of the CROI 2019 meeting in Seattle, Washington.
After years of pressure from prevention advocates, FDA has finally given the other rubber a new name - the internal condom – and a new classification.
"We are not yet at the stage where aspirin can be recommended for preventing HIV, but the potential for another tool in our belt against a virus that has killed 35 million people (almost the population of Canada), can only be good news."
The vaginal, anal, and gut microbiome regions are now the focus of intense HIV-related research, with potentially wide-ranging implications stretching from prevention to patient care.
Use of the dapivirine vaginal ring for pre-exposure prophylaxis (PrEP) does not lead to resistance mutations in women who seroconvert, Urvi Parikh, Ph.D., reported at the HIV Research for Prevention 2018 conference.